Clinical Trial Update: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma; the study is currently active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Melanoma Stage III | Phase 2 | Status: ACTIVE_NOT_RECRUITING